Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms - Poll - MDSpire

Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms

  • By

  • Christoph J Auernhammer

  • Katharina Wang

  • Umberto Maccio

  • Thomas Knösel

  • Maximilian P Hungbauer

  • Katharina Schilbach

  • Julian Maurer

  • Lea Peischer

  • Astrid Reul

  • Elena Kuzmenko

  • Edlira Luca

  • Julia Hamati

  • Diana Vetter

  • Jose Oberholzer

  • Ralph Fritsch

  • Karel Pacak

  • Ashley B Grossman

  • Felix Beuschlein

  • Martin Reincke

  • Constanze Hantel

  • Kathrin Zitzmann

  • Svenja Nölting

  • January 10, 2026

  • 0 min

Share

Original Source(s)

Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms

  • by Christoph J Auernhammer, Katharina Wang, Umberto Maccio, Thomas Knösel, Maximilian P Hungbauer, Katharina Schilbach, Julian Maurer, Lea Peischer, Astrid Reul, Elena Kuzmenko, Edlira Luca, Julia Hamati, Diana Vetter, Jose Oberholzer, Ralph Fritsch, Karel Pacak, Ashley B Grossman, Felix Beuschlein, Martin Reincke, Constanze Hantel, Kathrin Zitzmann, Svenja Nölting

  • January 10, 2026

Related Content

The Impact of Physical Activity Levels on Sexual Function in Breast Cancer Survivors: An Integrative Review

Sexual dysfunction is a lasting effect of treatment and can impact the quality of life of breast cancer survivors. This review examined the impact of different levels (none/low, moderate, and high) of physical activity on sexual outcomes in breast cancer survivors.

Gut microbiota and pediatric metabolic dysfunction–associated steatotic liver disease: clinical evidence and therapeutic implications

Pheochromocytoma complicated with acute myocardial infarction and cerebral infarction: a case report